About AIM VACCINE Company

Le Meridien Vaccines is a large private vaccine group with a full industrial chain in China. Its business covers the entire industry value chain from R&D to manufacturing to commercialization. In 2020, it achieved batch issuance of about 60 million doses, achieving sales of vaccine products to 31 provinces, autonomous regions and municipalities directly under the Central Government in China. Le Méridien Vaccines has five vaccine companies that have proven human vaccine platform technology, which greatly guarantees the speed and flexibility of research and development. Currently, the company has 8 commercialized vaccines for 6 disease fields and 23 innovative vaccines under development for 13 disease fields. The products in production and development cover all of the world's top ten vaccine products (based on global sales in 2020). Through ten years of development, the company has become an inclusive and enterprising business model and corporate culture, thereby continuously expanding and optimizing its existing business. Currently, it wholly owns 4 licensed vaccine manufacturers, namely Ami Hanxin, Ami Kanghuai, Ami Weixin, and Rongan Biotech. It owns 3 research institutes, including the R&D center, Le Meridien Explorer, which was built in 2018, and focuses on providing technical support for early and cutting-edge research for R&D departments in various factories. Le Méridien acquired Zhuhai Lifanda Biotechnology Co., Ltd. in 2021. The company is one of only 3 domestic companies that have obtained approval for clinical trials of the mRNA COVID-19 vaccine, and has an independent mRNA production and drug delivery technology platform. Le Meridien Vaccine Group has always adhered to the mission of “making conscientious vaccines and healthy for the world” and strictly controls the quality of vaccines. The company is equipped with a professional and dedicated sales team composed of more than 100 members with an average of more than 10 years of experience in drug or vaccine sales. The core business leadership team has an average of 12 years of vaccine commercialization experience with multinational pharmaceutical companies, and has had outstanding results in marketing major international vaccines (including the world's first HPV, IPV, and dTAP-IPV-HiB). Currently, the main products on sale include recombinant hepatitis B vaccine (Hanson yeast), freeze-dried human rabies vaccine (Vero cells), inactivated hepatitis A vaccine (human diploid cells), live attenuated mumps vaccine, bivalent renal syndrome hemorrhagic fever inactivated vaccine (Vero cells), and ACYW135 meningococcal polysaccharide vaccine (MPSV4).